FDA schedules advisory committee meeting on communications
This article was originally published in The Tan Sheet
Executive Summary
The Risk Communication Advisory Committee will discuss developments in FDA's ongoing communications programs at public meeting Nov. 8-9 in Silver Spring, Md. Potential discussion topics include FDA's Strategic Plan for Risk Communication, FDA's Transparency Initiative and "the challenges of effectively communicating with patients and caregivers about appropriate use of medical devices when a patient is prescribed a medical device for home use," according to a Sept. 20 Federal Register notice. FDA will accept requests to make oral presentations through Oct. 21 and written submissions through Oct. 29
|
The Risk Communication Advisory Committee will discuss developments in FDA's ongoing communications programs at public meeting Nov. 8-9 in Silver Spring, Md. Potential discussion topics include FDA's Strategic Plan for Risk Communication, FDA's Transparency Initiative and "the challenges of effectively communicating with patients and caregivers about appropriate use of medical devices when a patient is prescribed a medical device for home use," according to a Sept. 20 Federal Register notice. FDA will accept requests to make oral presentations through Oct. 21 and written submissions through Oct. 29. |